toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print
  Record Links
Author (up) Lin, Z.; Liao, Z.; Huang, J.; Ai, M.; Pan, Y.; Wu, H.; Lu, J.; Cao, S.; Li, L.; Wei, Q.; Tang, D.; Wei, Y.; Li, T.; Wu, Y.; Xu, M.; Li, Q.; Jin, O.; Yu, B.; Gu, J. url  doi
openurl 
  Title Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis Patients Type Journal Article
  Year 2015 Publication BioMed Research International Abbreviated Journal Biomed Res Int  
  Volume 2015 Issue Pages 876040  
  Keywords  
  Abstract Objectives. To evaluate the efficiency and the predictive factors of clinical response of infliximab in active nonradiographic axial spondyloarthritis patients. Methods. Active nonradiographic patients fulfilling ESSG criteria for SpA but not fulfilling modified New York criteria were included. All patients received infliximab treatment for 24 weeks. The primary endpoint was ASAS20 response at weeks 12 and 24. The abilities of baseline parameters and response at week 2 to predict ASAS20 response at weeks 12 and 24 were assessed using ROC curve and logistic regression analysis, respectively. Results. Of 70 axial SpA patients included, the proportions of patients achieving an ASAS20 response at weeks 2, 6, 12, and 24 were 85.7%, 88.6%, 87.1%, and 84.3%, respectively. Baseline MRI sacroiliitis score (AUC = 0.791; P = 0.005), CRP (AUC = 0.75; P = 0.017), and ASDAS (AUC = 0.778, P = 0.007) significantly predicted ASAS20 response at week 12. However, only ASDAS (AUC = 0.696, P = 0.040) significantly predicted ASAS20 response at week 24. Achievement of ASAS20 response after the first infliximab infusion was a significant predictor of subsequent ASAS20 response at weeks 12 and 24 (wald chi (2) = 6.87, P = 0.009, and wald chi (2) = 5.171, P = 0.023). Conclusions. Infliximab shows efficiency in active nonradiographic axial spondyloarthritis patients. ASDAS score and first-dose response could help predicting clinical efficacy of infliximab therapy in these patients.  
  Address Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Tianhe Road No. 600, Guangzhou 510630, China  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 2314-6141 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:26273654 Approved no  
  Call Number ref @ user @ Serial 73732  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: